Antecedent hypertension and heart failure after myocardial infarction
A. Mark Richards, MD, PhD ,*,
M. Gary Nicholls, MD, FACC*,
Richard W. Troughton, PhD*,
John G. Lainchbury, MD ,
John Elliott, MB, ChB, PhD ,
Christopher Frampton, PhD*,
Eric A. Espiner, MD*,
Ian G. Crozier, MD*,
Timothy G. Yandle, PhD* and
John Turner, MD
* Christchurch Cardioendocrine Research Group, Christchurch School of Medicine, Christchurch Hospital, Christchurch, New Zealand
Cardiology, Christchurch Hospital, Christchurch, New Zealand
Nuclear Medicine, Christchurch Hospital, Christchurch, New Zealand

View larger version (19K):
[in a new window]
|
Figure 2 Event-free survival curves for postdischarge all-cause mortality (Death; upper panel) and postdischarge heart failure requiring readmission to hospital (Heart Failure; lower panel) in normotensive (NT; single line) and hypertensive (HT; double line) patients after acute myocardial infarction. *p < 0.05, p < 0.001.
|
|

View larger version (27K):
[in a new window]
|
Figure 3 Event-free survival curves for postdischarge heart failure requiring readmission to hospital in normotensives (dotted and dashed lines; groups NT1 and NT2) and hypertensives (solid lines; groups HT1 and HT2) according to age (top panel), aminoterminal brain natriuretic peptide (N-BNP) (middle panel) and left ventricular systolic volume (LVESV) (lower panel) equal or below (dotted [NT1] and light solid [HT1] lines) and above (dashed [NT2] and heavy solid [HT2] lines) overall median values. Medians: age = 64.1 years; N-BNP 120 pmol/l; LVESV 78 ml. *p < 0.05, **p < 0.01, p < 0.001.
|
|
|